DDX21 连接 BRAFV600E 与 TERT 促进甲状腺癌进展
该研究通过免疫沉淀、质谱及 Co-IP 鉴定 TERT 互作蛋白,并在 60 对甲状腺癌与癌旁正常组织中检测 DDX21 表达,结合体外、体内实验及 RNA-seq、ChIP-seq、Ribo-seq 解析机制。结果提示 BRAFV600E 经 MEK/ERK/GABP 轴上调 DDX21,DDX21 与 TERT 互作促进 rRNA 转录并调控多个癌症标志基因,驱动甲状腺癌恶性进展。
要点
- BRAFV600E 经 MEK/ERK/GABP 轴上调 DDX21 表达。
- DDX21 与 TERT 互作,影响 Pol I 与 rDNA 结合以调控 rRNA 转录。
- DDX21 敲低抑制甲状腺癌细胞增殖、集落形成、迁移和侵袭。
核心结论
- BRAFV600E 通过 MEK/ERK/GABP 轴上调 DDX21,DDX21 与 TERT 互作促进 rRNA 转录并调控多个癌症标志基因,驱动甲状腺癌恶性进展。
- DDX21 被视为连接 BRAFV600E 与 TERT 之间 crosstalk 的介质,可能成为携带 BRAF 和 TERT 改变的甲状腺癌患者的治疗靶点。
研究设计与样本
- 通过免疫沉淀(IP)和质谱鉴定 TERT 互作蛋白,并用 Co-IP 验证。
- 在 60 对甲状腺癌与癌旁正常组织中检测 DDX21 表达,并在体外和体内探索 DDX21 在甲状腺癌中的功能。
- 整合 RNA-seq、ChIP-seq 和 Ribo-seq 分析以阐明分子机制,并使用 BRAF/MEK 抑制剂和 BRAFV600E 过表达研究 BRAF 突变对 DDX21 的调控。
- 采用 in silico 分析、ChIP 和荧光素酶报告实验鉴定结合 DDX21 启动子的转录因子。
主要发现
- DDX21 与 TERT 互作,通过影响 Pol I 与 rDNA 的结合调控 rRNA 转录。
- DDX21 在甲状腺癌中上调,DDX21 敲低降低多个癌症标志基因表达并抑制甲状腺癌细胞增殖、集落形成、迁移和侵袭。
- GABPA 结合 DDX21 启动子,敲低 GABPA 或 GABPB1 抑制 DDX21 启动子活性和转录。
- 在 BRAF 突变癌细胞中药理抑制 MAPK 通路降低 GABPA、GABPB1 和 DDX21 表达。
关键数值与推荐
- DDX21 表达在 60 对甲状腺癌与癌旁正常组织中检测。
- BRAFV600E 过表达与 BRAF/MEK 抑制剂用于研究 BRAF 突变对 DDX21 的调控。
- GABPA 结合 DDX21 启动子由 in silico 分析、ChIP 和荧光素酶报告实验鉴定。
临床怎么用
- 对携带 BRAF 和 TERT 改变的甲状腺癌患者,DDX21 可能作为潜在治疗靶点。
- MAPK 通路抑制可降低 GABPA、GABPB1 和 DDX21 表达,提示该轴可能影响 BRAF 突变甲状腺癌的分子干预。
- DDX21 高表达与甲状腺癌恶性表型相关,检测 DDX21 或有助于风险分层。
局限性
- 摘要未报告 DDX21 在 60 对组织中的具体表达数值或统计结果。
- 机制结论主要来自体外和体内实验,尚缺乏临床干预数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The coexistence of BRAFV600E and telomerase reverse transcriptase (TERT) promoter alterations has been reported to cooperatively upregulate TERT expression and is well recognized as a biomarker for aggressive thyroid cancer. However, the mechanism underlying their synergistic effect remains elusive. METHODS: TERT-interacting proteins were identified via immunoprecipitation (IP) and mass spectrometry and validated by Co-IP. DDX21 expression was detected in 60 paired thyroid cancer and adjacent normal tissues, and the function of DDX21 in thyroid cancer was explored in vitro and in vivo. Integrated analyses of RNA-seq, ChIP-seq, and Ribo-seq assays were conducted to elucidate the molecular mechanisms. BRAF/MEK inhibitors and BRAFV600E overexpression were used to investigate the regulation of DDX21 by BRAF mutation. In silico analysis, ChIP, and luciferase reporter assays were used to identify the transcription factors binding to DDX21 promoter. RESULTS: DDX21 interacted with TERT to regulate ribosomal RNA (rRNA) transcription by affecting the binding of Pol I to rDNA. DDX21 is upregulated in thyroid cancer, and DDX21 knockdown decreased the expression of multiple cancer hallmark genes and suppressed cell proliferation, colony formation, cell migration, and invasion of thyroid cancer cells. GABPA bound to the promoter of DDX21, and knockdown of GABPA or GABPB1 suppressed DDX21 promoter activity and transcription. Pharmacological inhibition of the MAPK pathway in BRAF-mutant cancer cells decreased the expression of GABPA, GABPB1, and DDX21. CONCLUSIONS: BRAFV600E upregulates expression of DDX21 through the MEK/ERK/GABP axis. DDX21, in turn, interacts with TERT to promote rRNA transcription and modulate the expression of multiple cancer hallmark genes, driving the malignant progression of thyroid cancer. These findings suggest that DDX21 acts as a mediator to bridge the crosstalk between BRAFV600E and TERT and may serve as a therapeutic target for patients with thyroid cancer harboring BRAF and TERT alterations.
引用
- Chen M, Jiang K, Zhang Q, et al. DDX21 Links BRAFV600E and TERT to Promote Thyroid Cancer Progression. Thyroid. 2026. PMID: 41817108. doi:10.1177/10507256261417697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。